

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUN - 1 2000

Richard A. Adams President Lifecare Imaging, Inc. 8411 Pyott Rd. Lake In The Hills, IL 60102 Re: K000987

VFSS Imager, Model SIS-300 Dated: March 24, 2000 Received: March 27, 2000 Regulatory class: II

21 CFR 892.1650/Procode: 90 JAA 21 CFR 892.1720/Procode: 90 IZL

Dear Mr. Adams:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours

Daniel G. Schultz, M.D. Captain, USPHS

Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation Center for Devices and Radiological Health

Enclosure(s)

Indications for Use

Ver/ 3 - 4/24/96

Applicant: LIFECARE IMAGING INTERNATIONAL

510(k) Number (if known): K000987

Device Name: VFSS Imager (Video Fluoroscopic Swallow Study Imager)

Indications For Use: The VFSS Imager is intended for use in fluoroscopically visualizing the swallowing function of patients with or suspected of having dysphasia.

The VFSS Imager may only be used by trained personnel (physicians, speech pathologists or radiological technologists); and a physician must prescribe the procedure.

The patient typically sits in a wheelchair while being fed various food viscosities by a speech pathologist. The swallow is observed on the video monitor and recorded on videotape for later review by a radiologist.

The typical procedure is preformed at 60 kV 1.2 mA with a fluoro time of approximately four minutes.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Per 21 CFR 801.109)

(Optional Format 1-2-96)

Prescription Use _____(Per 21 CFR 801.109)

(Division Sign-Off)

Division of Reproductive, Abdominal, ENT,

and Radiological Devices

510(k) Number <u>K000987</u>